I agree that market cap is ridiculously cheap given where ATH are currently. If the market cap doesn’t improve significantly towards the end of the year then any BP offer end of phase 2 trials will not realise the full value unless there is significant interest and competitive bids. Apart from the ASX announcement I didn’t see much on the web about the latest results. ATH still doesn’t seem to be on the radar of investors to get any upward momentum in share price. A bit more publicity is required now that the results are forthcoming and looking good.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-76
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $648.3K | 128.1M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4901441 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22097257 | 20 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |